Combing daily cyclophosphamide and weekly methotrexate given concurrently with daily celecoxib failed to achieve objective response in heavily pretreated patients with metastatic cancers in a phase 2 trial. Of 67 patients with breast, gastrointestinal, renal, skin, ovary, or prostate cancer, only 34.3% achieved stable disease of more than 4 months. The treatment, however, was well tolerated, with a low incidence of hematologic and nonhematologic adverse events. The researchers concluded that their data do not support the basic tenets of metronomic chemotherapy to overcome advance tumors by targeting blood vessels.
Complete results are published online in the May 17 edition of the British Journal of Cancer (http://www.nature.com.proxy.libraries.rutgers.edu/bjc/journal/vaop/ncurrent/pdf/bjc2011154a.pdf).